Innovent Biologics Inc (6IB) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.029x

Based on the latest financial reports, Innovent Biologics Inc (6IB) has a cash flow conversion efficiency ratio of -0.029x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-311.45 Million ≈ $-364.11 Million USD) by net assets (€10.78 Billion ≈ $12.61 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Innovent Biologics Inc (6IB) defensive interval to measure how many days the company can operate on defensive assets alone.

Innovent Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Innovent Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Innovent Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Innovent Biologics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
PTT Exploration and Production Public Company Limited BK:PTTEP	0.085x
Wipro Limited F:WIOA	0.047x
Lingyi iTech Guangdong Co SHE:002600	0.086x
Capgemini SE PA:CAP	0.183x
Hyundai Rotem Co KO:064350	-0.010x
Hitachi Energy India Limited NSE:POWERINDIA	0.191x
Trent Limited NSE:TRENT	0.216x
FIBRA Prologis MX:FIBRAPL14	0.017x

Annual Cash Flow Conversion Efficiency for Innovent Biologics Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of Innovent Biologics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 6IB market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€19.36 Billion ≈ $22.63 Billion	€10.00 Billion ≈ $11.69 Billion	0.517x	+426.62%
2024-12-31	€13.12 Billion ≈ $15.34 Billion	€1.29 Billion ≈ $1.50 Billion	0.098x	+731.56%
2023-12-31	€12.53 Billion ≈ $14.65 Billion	€147.81 Million ≈ $172.81 Million	0.012x	+106.60%
2022-12-31	€10.73 Billion ≈ $12.54 Billion	€-1.92 Billion ≈ $-2.24 Billion	-0.179x	+8.77%
2021-12-31	€10.33 Billion ≈ $12.08 Billion	€-2.02 Billion ≈ $-2.37 Billion	-0.196x	-459.30%
2020-12-31	€8.78 Billion ≈ $10.26 Billion	€-307.69 Million ≈ $-359.72 Million	-0.035x	+89.99%
2019-12-31	€4.76 Billion ≈ $5.56 Billion	€-1.66 Billion ≈ $-1.95 Billion	-0.350x	-45.07%
2018-12-31	€4.19 Billion ≈ $4.90 Billion	€-1.01 Billion ≈ $-1.18 Billion	-0.241x	-179.49%
2017-12-31	€-1.62 Billion ≈ $-1.90 Billion	€-492.27 Million ≈ $-575.52 Million	0.303x	-19.89%
2016-12-31	€-958.22 Million ≈ $-1.12 Billion	€-362.99 Million ≈ $-424.38 Million	0.379x	--

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$16.83 Billion

€14.39 Billion EUR

Market Cap Rank

#1515 Global

#333 in Germany

Share Price

€8.30

Change (1 day)

+2.28%

52-Week Range

€7.96 - €11.60

All Time High

€11.80